[go: up one dir, main page]

WO2002022127A1 - Utilisation d"inhibiteurs de phosphodiesterase pour le traitement de trouble ano-rectal - Google Patents

Utilisation d"inhibiteurs de phosphodiesterase pour le traitement de trouble ano-rectal Download PDF

Info

Publication number
WO2002022127A1
WO2002022127A1 PCT/GB2000/003510 GB0003510W WO0222127A1 WO 2002022127 A1 WO2002022127 A1 WO 2002022127A1 GB 0003510 W GB0003510 W GB 0003510W WO 0222127 A1 WO0222127 A1 WO 0222127A1
Authority
WO
WIPO (PCT)
Prior art keywords
phosphodiesterase
treatment
present
inhibitors
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/003510
Other languages
English (en)
Inventor
Oliver Jones
Alison Frances Brading
Neil James Mccready Mortensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to PCT/GB2000/003510 priority Critical patent/WO2002022127A1/fr
Priority to AU2000270300A priority patent/AU2000270300A1/en
Publication of WO2002022127A1 publication Critical patent/WO2002022127A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • the present invention relates to treatment of anorectal disorders such as anal fissure.
  • Anal fissure can be an acute condition manifested as a longitudinal tear in the epithelium of the anal canal, or a chronic condition in which an acute tear does not heal and an ovoid ulcer forms.
  • the smooth muscle of the anus typically undergoes spasm, causing pain to the affected individual.
  • GTN Glyceryl trinitrate
  • a second class of drug, calcium channel blocking drugs have the advantage that they may be give in oral or topical form.
  • Healing rates are similar for those for GTN, but patients are similarly affected by headache [Cook TA, et al Br. J. Surg. 1999 86: 1269-73].
  • botulinum toxin injections have been used either into the internal sphincter [Maria G et al, N. Engl. J. Med. 1998 338: 217-20], the intersphincteric space [Minguez M et al, Dis. Colon. Rectum. 1999 42: 1016-21.], or the external sphincter [Madalinski M et al, Endoscopy 1999 31 : S63.].
  • This treatment has resulted in higher healing rates in some studies [Brisinda G, et ⁇ /.,.N,.Engl. J. Med...l999 341: 65-9.], but is expensive and can

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L"invention concerne un procédé relatif au traitement de trouble ano-rectal chez un mammifère, qui consiste à administrer au sujet une quantité efficace d"inhibiteur de phosphodiestérase, et l"invention concerne également des préparations pharmaceutiques destinées à être utilisées dans le cadre du procédé.
PCT/GB2000/003510 2000-09-13 2000-09-13 Utilisation d"inhibiteurs de phosphodiesterase pour le traitement de trouble ano-rectal Ceased WO2002022127A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/GB2000/003510 WO2002022127A1 (fr) 2000-09-13 2000-09-13 Utilisation d"inhibiteurs de phosphodiesterase pour le traitement de trouble ano-rectal
AU2000270300A AU2000270300A1 (en) 2000-09-13 2000-09-13 Use of phosphodiesterase inhibitors for the treatment of anorectal disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/003510 WO2002022127A1 (fr) 2000-09-13 2000-09-13 Utilisation d"inhibiteurs de phosphodiesterase pour le traitement de trouble ano-rectal

Publications (1)

Publication Number Publication Date
WO2002022127A1 true WO2002022127A1 (fr) 2002-03-21

Family

ID=9885671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003510 Ceased WO2002022127A1 (fr) 2000-09-13 2000-09-13 Utilisation d"inhibiteurs de phosphodiesterase pour le traitement de trouble ano-rectal

Country Status (2)

Country Link
AU (1) AU2000270300A1 (fr)
WO (1) WO2002022127A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140181A3 (fr) * 2006-05-26 2008-08-14 King Pharmaceuticals Res & Dev Polythérapie comprenant un inhibiteur de fixation de l'adénosine et un antagoniste des récepteurs de l'adénosine non sélectif
CN101744822B (zh) * 2008-12-14 2011-03-23 鲁南制药集团股份有限公司 一种治疗痔疮的药物组合物
US7915265B2 (en) 2001-10-05 2011-03-29 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
CN101744821B (zh) 2008-12-14 2011-06-08 鲁南制药集团股份有限公司 己酮可可碱在制备治疗肛肠疾病药物中的应用
US8080553B2 (en) 2003-10-15 2011-12-20 Zalicus Inc. Methods and reagents for the treatment of immunoinflammatory disorders

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486436A (en) * 1982-07-22 1984-12-04 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
DE3800301A1 (de) * 1988-01-08 1989-07-20 Rudolf Leitz Procainhaltige salbe und ihre verwendung
RO103863B1 (ro) * 1989-03-22 1992-04-26 Institutul De Cercetari Chimico-Farmaceutice Supozitoare cu actiune antispastica si cicatrizanta
US5145852A (en) * 1989-07-11 1992-09-08 Ronald Virag Vaso-active medicament to treat impotence
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
WO1998019672A1 (fr) * 1996-11-01 1998-05-14 Nitromed Inc. Composes nitroses et nitrosyles inhibiteurs de la phosphodiesterase, compositions comprenant ces composes et utilisations correspondantes
WO1998037894A1 (fr) * 1997-02-28 1998-09-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Combinaison synergique d'inhibiteurs de la phosphodiesterase et d'agonistes de la cyclase d'adenylate ou d'agonistes de la cyclyse guanylique
WO1998041232A2 (fr) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Procedes et compositions permettant de moduler la sensibilite aux corticosteroides
WO1999030697A2 (fr) * 1997-12-16 1999-06-24 Pfizer Products Inc. Composition efficace pour le traitement de l'impuissance
RU2144354C1 (ru) * 1997-10-27 2000-01-20 Козырев Валентин Архипович Способ лечения ночного недержания мочи
WO2000024745A1 (fr) * 1998-10-23 2000-05-04 Pfizer Limited INHIBITEURS DE cGMP PDE5 DE PYRAZOLOPYRIMIDINONE SERVANT A TRAITER LE DYSFONCTIONNEMENT SEXUEL
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO2000035434A2 (fr) * 1998-12-14 2000-06-22 Cellegy Pharmaceuticals, Inc. Compositions et techniques de traitement de troubles anorectaux
WO2000042018A1 (fr) * 1999-01-15 2000-07-20 Byk Gulden Lomberg Chemische Fabrik Gmbh 6-phenylphenanthridines polysubstitues a activite inhibant pde-iv

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486436A (en) * 1982-07-22 1984-12-04 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
DE3800301A1 (de) * 1988-01-08 1989-07-20 Rudolf Leitz Procainhaltige salbe und ihre verwendung
RO103863B1 (ro) * 1989-03-22 1992-04-26 Institutul De Cercetari Chimico-Farmaceutice Supozitoare cu actiune antispastica si cicatrizanta
US5145852A (en) * 1989-07-11 1992-09-08 Ronald Virag Vaso-active medicament to treat impotence
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1998019672A1 (fr) * 1996-11-01 1998-05-14 Nitromed Inc. Composes nitroses et nitrosyles inhibiteurs de la phosphodiesterase, compositions comprenant ces composes et utilisations correspondantes
WO1998037894A1 (fr) * 1997-02-28 1998-09-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Combinaison synergique d'inhibiteurs de la phosphodiesterase et d'agonistes de la cyclase d'adenylate ou d'agonistes de la cyclyse guanylique
WO1998041232A2 (fr) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Procedes et compositions permettant de moduler la sensibilite aux corticosteroides
RU2144354C1 (ru) * 1997-10-27 2000-01-20 Козырев Валентин Архипович Способ лечения ночного недержания мочи
WO1999030697A2 (fr) * 1997-12-16 1999-06-24 Pfizer Products Inc. Composition efficace pour le traitement de l'impuissance
WO2000024745A1 (fr) * 1998-10-23 2000-05-04 Pfizer Limited INHIBITEURS DE cGMP PDE5 DE PYRAZOLOPYRIMIDINONE SERVANT A TRAITER LE DYSFONCTIONNEMENT SEXUEL
WO2000035434A2 (fr) * 1998-12-14 2000-06-22 Cellegy Pharmaceuticals, Inc. Compositions et techniques de traitement de troubles anorectaux
WO2000042018A1 (fr) * 1999-01-15 2000-07-20 Byk Gulden Lomberg Chemische Fabrik Gmbh 6-phenylphenanthridines polysubstitues a activite inhibant pde-iv

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IONESCU, MIOARA ET AL: "Formulation of antispastic and cicatrizant suppositories", XP002170195, retrieved from STN Database accession no. 121:263690 *
DATABASE WPI Week 200051, Derwent World Patents Index; AN 2000-557073, XP002170196, KOZYREV V.A.: "Method of nocturnal enuresis treatment" *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915265B2 (en) 2001-10-05 2011-03-29 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
US8080553B2 (en) 2003-10-15 2011-12-20 Zalicus Inc. Methods and reagents for the treatment of immunoinflammatory disorders
WO2007140181A3 (fr) * 2006-05-26 2008-08-14 King Pharmaceuticals Res & Dev Polythérapie comprenant un inhibiteur de fixation de l'adénosine et un antagoniste des récepteurs de l'adénosine non sélectif
CN101744822B (zh) * 2008-12-14 2011-03-23 鲁南制药集团股份有限公司 一种治疗痔疮的药物组合物
CN101744821B (zh) 2008-12-14 2011-06-08 鲁南制药集团股份有限公司 己酮可可碱在制备治疗肛肠疾病药物中的应用

Also Published As

Publication number Publication date
AU2000270300A1 (en) 2002-03-26

Similar Documents

Publication Publication Date Title
US7919484B2 (en) Combination therapy
JP2020109130A (ja) 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
US20050014783A1 (en) Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
JP2001517639A (ja) 鼻炎／結膜炎および感冒、感冒に似た症状および／または流行性感冒の症状を局所的に治療するための、鎮静作用を有しない抗ヒスタミンおよびα−アドレナリン作動薬を含む組合せ物の使用
JPS61277620A (ja) 排尿困難治療剤
JP2002527392A (ja) 末梢的に作用する抗掻痒アヘン剤
US20030176421A1 (en) Prokinetic agents for treating gastric hypomotility and related disorders
AU2003228991B2 (en) Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
JPH10158169A (ja) 塩化トロスピウムを含んだ医薬製剤、その調整方法および使用方法
MX2007009187A (es) El uso de flupirtina para el tratamiento de vejiga superactiva y enfermedades asociadas, y para el tratamiento del sindrome del intestino irritable.
JP2006511624A (ja) α２δサブユニット・カルシウム・チャンネル調節因子を使用する無痛性膀胱障害を処置するための方法
JP2000198734A (ja) 胃運動性減弱および関連疾患の治療のための運動性増強薬
WO2002022127A1 (fr) Utilisation d"inhibiteurs de phosphodiesterase pour le traitement de trouble ano-rectal
US7223754B2 (en) Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders
US7879898B1 (en) Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
JP2005516977A (ja) 尿失禁の処置での４−（２−フルオロフェニル）−６−メチル−２−（１−ピペラジニル）チエノ（２，３−ｄ−ピリミジン）の使用
WO1998037887A1 (fr) Composition anticancereuse comprenant un derive de diaminotrifluoromethylpyridine
JPWO2006118212A1 (ja) 膵炎の予防および治療剤
CN113242735A (zh) 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作
JP2001504484A (ja) ネファゾドンの外傷後ストレス障害における使用
KR100863758B1 (ko) 항문직장 장애의 치료 조성물 및 방법
RU2229885C2 (ru) Средство для лечения нарушения функции эрекции
JP4686704B2 (ja) 動脈瘤予防および／または治療剤
JP2000355551A (ja) 医薬組成物
JPS6132286B2 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP